\-\ Texto\\:\\ \ \(0\)\
\-\ pertinent\\ physical\\ exam\\ findings\\ included\\:\ \(0\)\
\-\ \\Â\\»\\ splenomegaly\\ to\\ 1\\ cm\\ below\\ the\\ costal\\ margin\ \(1\)\
\-\ \\Â\\»\\ mild\\ tenderness\\ to\\ palpation\\ in\\ the\\ left\\ upper\\ quadrant\ \(1\)\
\-\ \\Â\\»\\ 1\\-2\\ cm\\ firm\\ immobile\\ nodule\\ left\\ midclavicular\\ costovertebral\\ margin\ \(1\)\
\-\ \\Â\\»\\ midline\\ tenderness\\ to\\ t12\\ and\\ l1\ \(0\)\
\-\ \\Â\\»\\ decreased\\ range\\ of\\ motion\\ in\\ flexion\\ secondary\\ to\\ pain\\.\ \(1\)\
\-\ wbc\\:\\ 9\\.39\\ hgb\\:11\\.2\\ hct\\:35\\.7\\ plt\\:535\\ esr\\:117\ \(0\)\
\-\ the\\ patient\\ was\\ placed\\ on\\ amphotericin\\ b\\ and\\ fluconazole\\ and\\ was\\ discharged\\ from\\ the\\ hospital\\.\\ however\\,\\ he\\ returned\\ to\\ the\\ hospital\\ one\\ month\\ later\\ with\\ worsening\\ back\\ pain\\.\\ imaging\\ demonstrated\\ progressive\\ disease\\.\\ he\\ was\\ placed\\ on\\ multiple\\ antifungal\\ therapies\\ with\\ no\\ success\\.\\ the\\ patient\\ was\\ then\\ placed\\ on\\ interferon\\ gamma\\ and\\ posaconazole\\ with\\ noted\\ improvement\\.\ \(0\)\
\-\ the\\ frontal\\ and\\ lateral\\ views\\ of\\ the\\ thoracic\\ spine\\ demonstrate\\ a\\ mixed\\ lucent\\/sclerotic\\ appearance\\ of\\ the\\ t12\\ vertebral\\ body\\ and\\ the\\ left\\ pedicle\\.\\ \ \(0\)\
\-\ a\\ sagittal\\ view\\ mri\\ with\\ gadolinium\\ of\\ the\\ thoracic\\ spine\\ and\\ lumbar\\ spine\\ demonstrates\\ enhancing\\ lesions\\ multiple\\ vertebrae\\,\\ including\\ t12\\.\\ \\ soft\\ tissue\\ enhancement\\ is\\ also\\ present\\ from\\ t9\\-l2\\ paraspinal\\ muscles\\.\\ \ \(0\)\
\-\ a\\ sagittal\\ nonconstrast\\ ct\\ obtained\\ several\\ weeks\\ later\\ demonstrates\\ worsening\\ expansile\\ lytic\\ lesions\\ to\\ t10\\,\\ t11\\,\\ and\\ t12\\.\ \(0\)\
\-\ mri\\ of\\ the\\ thoracic\\ spine\\ was\\ obtained\\ five\\ months\\ after\\ the\\ patient\\ began\\ treatment\\.\\ \\ interval\\ worsening\\ present\\ at\\ multiple\\ levels\\,\\ including\\ multiple\\ compression\\ deformities\\ and\\ enhancing\\ mass\\ with\\ cortical\\ disruption\\ and\\ contiguous\\ anterior\\ soft\\ tissue\\ mass\\ lifting\\ the\\ anterior\\ longitudinal\\ ligament\\.\\ \\ involvment\\ of\\ the\\ posterior\\ elements\\ is\\ present\\ with\\ narrowing\\ of\\ multiple\\ neural\\ foramina\\ and\\ spinal\\ cord\\ compression\\.\ \(0\)\
\-\ disseminated\\ coccidioidomycosis\ \(1\)\
\-\ \\-osteomyelitis\\,\\ including\\ mycobacterial\\ and\\ fungal\\.\ \(0\)\
\-\ \\-metastatic\\ disease\ \(3\)\
\-\ \\-multiple\\ myeloma\ \(0\)\
\-\ the\\ patient\\ is\\ a\\ 23\\ year\\ old\\ man\\ who\\ presented\\ with\\ four\\ weeks\\ of\\ persistent\\ mid\\ back\\ pain\\.\\ he\\ received\\ pain\\ medications\\ with\\ minimal\\ relief\\.\\ his\\ pain\\ gradually\\ worsened\\ over\\ three\\ months\\ to\\ involve\\ his\\ left\\ leg\\ and\\ hip\\.\\ the\\ patient\\ had\\ associated\\ fevers\\,\\ weight\\ loss\\,\\ night\\ sweats\\,\\ fatigue\\,\\ and\\ intermittent\\ abdominal\\ pain\\.\ \(0\)\
\-\ coccidioidomyocosis\\ is\\ a\\ common\\ fungal\\ infection\\ in\\ the\\ southwestern\\ united\\ states\\.\\ it\\ usually\\ leads\\ to\\ a\\ self\\ limited\\ pulmonary\\ infection\\.\\ however\\,\\ in\\ less\\ than\\ 5\\%\\ of\\ cases\\,\\ the\\ infection\\ can\\ disseminate\\ to\\ the\\ soft\\ tissue\\,\\ meninges\\,\\ and\\ bone\\.\\ those\\ who\\ are\\ most\\ susceptible\\ to\\ dissemination\\ include\\ the\\ immunocompromised\\,\\ pregnant\\ women\\,\\ and\\ certain\\ ethnic\\ groups\\,\\ such\\ as\\ latinos\\,\\ filipinos\\,\\ and\\ african\\ americans\\.\\ the\\ most\\ common\\ antifunals\\ used\\ to\\ treat\\ disseminated\\ coccidioidomycosis\\ includes\\ amphotericin\\ b\\ and\\ the\\ azoles\\.\\ the\\ patient\\ was\\ initially\\ placed\\ on\\ amphotericin\\ b\\ and\\ fluconazole\\,\\ but\\ his\\ disease\\ progressed\\.\\ he\\ was\\ placed\\ on\\ itraconazole\\ and\\ posaconazole\\ with\\ no\\ improvement\\.\\ he\\ was\\ then\\ placed\\ on\\ interferon\\ gamma\\ because\\ it\\ was\\ believed\\ that\\ his\\ immune\\ system\\ was\\ unable\\ to\\ recognize\\ coccidiodes\\.\\ he\\ was\\ also\\ placed\\ on\\ posaconazole\\,\\ after\\ which\\ he\\ improved\\.\\ he\\ was\\ discharged\\ from\\ the\\ hospital\\.\\ he\\ will\\ require\\ lifelong\\ antifungal\\ therapy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ placed\\:\\ 0\\.24375446273227058\ \(0\)\
\-\ he\\:\\ 0\\.2381613074137997\ \(0\)\
\-\ the\\:\\ 0\\.22291996042519446\ \(0\)\
\-\ posaconazole\\:\\ 0\\.21439567432596987\ \(0\)\
\-\ t12\\:\\ 0\\.2043036931356548\ \(0\)\
\-\ was\\:\\ 0\\.18688891472295102\ \(0\)\
\-\ and\\:\\ 0\\.18468297028513755\ \(0\)\
\-\ amphotericin\\:\\ 0\\.17040494527683192\ \(0\)\
\-\ to\\:\\ 0\\.13406179139384716\ \(0\)\
\-\ multiple\\:\\ 0\\.13114611022879888\ \(0\)\
\-\ fluconazole\\:\\ 0\\.1257175353095875\ \(0\)\
\-\ antifungal\\:\\ 0\\.12330232253667711\ \(0\)\
\-\ interferon\\:\\ 0\\.11936476080888647\ \(0\)\
\-\ spine\\:\\ 0\\.11808229935886493\ \(0\)\
\-\ coccidioidomycosis\\:\\ 0\\.1162206784903906\ \(0\)\
\-\ his\\:\\ 0\\.10840784473347655\ \(0\)\
\-\ worsening\\:\\ 0\\.10237577187601582\ \(0\)\
\-\ thoracic\\:\\ 0\\.1001813127080147\ \(0\)\
\-\ hospital\\:\\ 0\\.09902598194925127\ \(0\)\
\-\ disseminated\\:\\ 0\\.09679736314773763\ \(0\)\
\-\ gamma\\:\\ 0\\.0963903826101622\ \(0\)\
\-\ pain\\:\\ 0\\.09594523908261088\ \(0\)\
\-\ including\\:\\ 0\\.0959420174261372\ \(0\)\
\-\ on\\:\\ 0\\.09447498729015699\ \(0\)\
\-\ patient\\:\\ 0\\.08720782658195955\ \(0\)\
\-\ infection\\:\\ 0\\.08098171558829029\ \(0\)\
\-\ fungal\\:\\ 0\\.08000228352833667\ \(0\)\
\-\ with\\:\\ 0\\.07875354310772549\ \(0\)\
\-\ of\\:\\ 0\\.07870651598318026\ \(0\)\
\-\ margin\\:\\ 0\\.07839391161355785\ \(0\)\
\-\ improvement\\:\\ 0\\.07801635431420093\ \(0\)\
\-\ discharged\\:\\ 0\\.0767049689885087\ \(0\)\
\-\ nonconstrast\\:\\ 0\\.0714652247753233\ \(0\)\
\-\ coccidioidomyocosis\\:\\ 0\\.0714652247753233\ \(0\)\
\-\ southwestern\\:\\ 0\\.0714652247753233\ \(0\)\
\-\ latinos\\:\\ 0\\.0714652247753233\ \(0\)\
\-\ filipinos\\:\\ 0\\.0714652247753233\ \(0\)\
\-\ antifunals\\:\\ 0\\.0714652247753233\ \(0\)\
\-\ azoles\\:\\ 0\\.0714652247753233\ \(0\)\
\-\ soft\\:\\ 0\\.07137220570899465\ \(0\)\
\-\ tissue\\:\\ 0\\.07032634662143032\ \(0\)\
\-\ present\\:\\ 0\\.06879199987996241\ \(0\)\
\-\ sagittal\\:\\ 0\\.06872430916632051\ \(0\)\
\-\ coccidiodes\\:\\ 0\\.06828883752497278\ \(0\)\
\-\ disseminate\\:\\ 0\\.06603515490514428\ \(0\)\
\-\ ethnic\\:\\ 0\\.06603515490514428\ \(0\)\
\-\ compression\\:\\ 0\\.06544958274575897\ \(0\)\
\-\ later\\:\\ 0\\.06396134495075814\ \(0\)\
\-\ then\\:\\ 0\\.06326708524859609\ \(0\)\
\-\ obtained\\:\\ 0\\.06321865284605224\ \(0\)\
\-\ midclavicular\\:\\ 0\\.061651161268338556\ \(0\)\
\-\ left\\:\\ 0\\.06097568034178046\ \(0\)\
\-\ americans\\:\\ 0\\.059682380404443236\ \(0\)\
\-\ itraconazole\\:\\ 0\\.059682380404443236\ \(0\)\
\-\ lifelong\\:\\ 0\\.059682380404443236\ \(0\)\
\-\ back\\:\\ 0\\.05960683818937188\ \(0\)\
\-\ involvment\\:\\ 0\\.058856992986553267\ \(0\)\
\-\ immobile\\:\\ 0\\.0581103392451953\ \(0\)\
\-\ costovertebral\\:\\ 0\\.0581103392451953\ \(0\)\
\-\ dissemination\\:\\ 0\\.0581103392451953\ \(0\)\
\-\ disease\\:\\ 0\\.05627481960790991\ \(0\)\
\-\ costal\\:\\ 0\\.05622109139815954\ \(0\)\
\-\ susceptible\\:\\ 0\\.05622109139815954\ \(0\)\
\-\ tenderness\\:\\ 0\\.05604933162778233\ \(0\)\
\-\ enhancing\\:\\ 0\\.05598824823756029\ \(0\)\
\-\ immunocompromised\\:\\ 0\\.05517501516478625\ \(0\)\
\-\ meninges\\:\\ 0\\.05425231053426422\ \(0\)\
\-\ mycobacterial\\:\\ 0\\.05382875144404783\ \(0\)\
\-\ recognize\\:\\ 0\\.05382875144404783\ \(0\)\
\-\ weeks\\:\\ 0\\.05356432867379132\ \(0\)\
\-\ from\\:\\ 0\\.05324407826155238\ \(0\)\
\-\ however\\:\\ 0\\.05289968642275658\ \(0\)\
\-\ t10\\:\\ 0\\.052680269375016284\ \(0\)\
\-\ therapies\\:\\ 0\\.052332037162029076\ \(0\)\
\-\ months\\:\\ 0\\.05202361458986499\ \(0\)\
\-\ splenomegaly\\:\\ 0\\.05199862791443572\ \(0\)\
\-\ cm\\:\\ 0\\.05132920834054335\ \(0\)\
\-\ lesions\\:\\ 0\\.05132920834054335\ \(0\)\
\-\ pedicle\\:\\ 0\\.0510759232839137\ \(0\)\
\-\ t11\\:\\ 0\\.05079102152798052\ \(0\)\
\-\ common\\:\\ 0\\.050685992437489696\ \(0\)\
\-\ who\\:\\ 0\\.050556147469927884\ \(0\)\
\-\ certain\\:\\ 0\\.050516118413957804\ \(0\)\
\-\ groups\\:\\ 0\\.050516118413957804\ \(0\)\
\-\ lifting\\:\\ 0\\.04999366252951849\ \(0\)\
\-\ anterior\\:\\ 0\\.04990190567265031\ \(0\)\
\-\ immune\\:\\ 0\\.049744945294607226\ \(0\)\
\-\ is\\:\\ 0\\.048952027812616976\ \(0\)\
\-\ united\\:\\ 0\\.048822240664085206\ \(0\)\
\-\ success\\:\\ 0\\.04839868157386881\ \(0\)\
\-\ l1\\:\\ 0\\.0481951913050811\ \(0\)\
\-\ foramina\\:\\ 0\\.0481951913050811\ \(0\)\
\-\ believed\\:\\ 0\\.04780341292730847\ \(0\)\
\-\ pregnant\\:\\ 0\\.046901967291850054\ \(0\)\
\-\ gradually\\:\\ 0\\.046568558044256705\ \(0\)\
\-\ most\\:\\ 0\\.04651357601640149\ \(0\)\
\-\ myeloma\\:\\ 0\\.0464070278911748\ \(0\)\
\-\ progressed\\:\\ 0\\.0464070278911748\ \(0\)\
\-\ vertebrae\\:\\ 0\\.046248761197783234\ \(0\)\
\-\ contiguous\\:\\ 0\\.04609362870522299\ \(0\)\
\-\ self\\:\\ 0\\.045941508685252604\ \(0\)\
\-\ mri\\:\\ 0\\.045877312724093455\ \(0\)\
\-\ it\\:\\ 0\\.04574993096759623\ \(0\)\
\-\ sweats\\:\\ 0\\.045645853413734686\ \(0\)\
\-\ pertinent\\:\\ 0\\.045360951657801504\ \(0\)\
\-\ deformities\\:\\ 0\\.045360951657801504\ \(0\)\
\-\ treat\\:\\ 0\\.04522229432351829\ \(0\)\
\-\ leads\\:\\ 0\\.04508604854377879\ \(0\)\
\-\ demonstrates\\:\\ 0\\.04490114359526428\ \(0\)\
\-\ worsened\\:\\ 0\\.04456359265933948\ \(0\)\
\-\ in\\:\\ 0\\.044467313178086054\ \(0\)\
\-\ elements\\:\\ 0\\.04431487542442821\ \(0\)\
\-\ paraspinal\\:\\ 0\\.04350173810265975\ \(0\)\
\-\ after\\:\\ 0\\.04335738911420609\ \(0\)\
\-\ fatigue\\:\\ 0\\.04328411480663381\ \(0\)\
\-\ longitudinal\\:\\ 0\\.04246946616338416\ \(0\)\
\-\ also\\:\\ 0\\.042039546682398544\ \(0\)\
\-\ returned\\:\\ 0\\.0420002280232011\ \(0\)\
\-\ relief\\:\\ 0\\.04190966129342827\ \(0\)\
\-\ began\\:\\ 0\\.041557515048446875\ \(0\)\
\-\ neural\\:\\ 0\\.04138720540898895\ \(0\)\
\-\ firm\\:\\ 0\\.04051143881507358\ \(0\)\
\-\ expansile\\:\\ 0\\.04043647235903898\ \(0\)\
\-\ interval\\:\\ 0\\.04043647235903898\ \(0\)\
\-\ five\\:\\ 0\\.040362216496217566\ \(0\)\
\-\ disruption\\:\\ 0\\.040362216496217566\ \(0\)\
\-\ african\\:\\ 0\\.040362216496217566\ \(0\)\
\-\ women\\:\\ 0\\.040215783543555664\ \(0\)\
\-\ night\\:\\ 0\\.04014358086771321\ \(0\)\
\-\ improved\\:\\ 0\\.03965597867359977\ \(0\)\
\-\ fevers\\:\\ 0\\.03945595244858877\ \(0\)\
\-\ involve\\:\\ 0\\.03932538384488828\ \(0\)\
\-\ states\\:\\ 0\\.03926090665067735\ \(0\)\
\-\ received\\:\\ 0\\.038884805554249204\ \(0\)\
\-\ unable\\:\\ 0\\.03870331632062974\ \(0\)\
\-\ included\\:\\ 0\\.038643742384307726\ \(0\)\
\-\ osteomyelitis\\:\\ 0\\.03852593663239993\ \(0\)\
\-\ ligament\\:\\ 0\\.03840987621521548\ \(0\)\
\-\ require\\:\\ 0\\.03840987621521548\ \(0\)\
\-\ muscles\\:\\ 0\\.03829551017132052\ \(0\)\
\-\ those\\:\\ 0\\.038238947218926504\ \(0\)\
\-\ flexion\\:\\ 0\\.03796210092372717\ \(0\)\
\-\ lytic\\:\\ 0\\.03764230407725369\ \(0\)\
\-\ medications\\:\\ 0\\.037487171584693446\ \(0\)\
\-\ gadolinium\\:\\ 0\\.03723525486643227\ \(0\)\
\-\ mixed\\:\\ 0\\.03699118731107588\ \(0\)\
\-\ 23\\:\\ 0\\.03684831523796319\ \(0\)\
\-\ below\\:\\ 0\\.036801264436627484\ \(0\)\
\-\ intermittent\\:\\ 0\\.03652474391062971\ \(0\)\
\-\ four\\:\\ 0\\.036214008875315166\ \(0\)\
\-\ lumbar\\:\\ 0\\.03608451940032682\ \(0\)\
\-\ limited\\:\\ 0\\.03566772244680426\ \(0\)\
\-\ levels\\:\\ 0\\.03542788938362097\ \(0\)\
\-\ nodule\\:\\ 0\\.03527198503679405\ \(0\)\
\-\ views\\:\\ 0\\.03527198503679405\ \(0\)\
\-\ initially\\:\\ 0\\.03504379604374081\ \(0\)\
\-\ includes\\:\\ 0\\.034749529152354734\ \(0\)\
\-\ range\\:\\ 0\\.03467765768610427\ \(0\)\
\-\ motion\\:\\ 0\\.034641967716067236\ \(0\)\
\-\ narrowing\\:\\ 0\\.034641967716067236\ \(0\)\
\-\ persistent\\:\\ 0\\.0344311764822838\ \(0\)\
\-\ hip\\:\\ 0\\.03432787034956388\ \(0\)\
\-\ progressive\\:\\ 0\\.03422590880342076\ \(0\)\
\-\ mass\\:\\ 0\\.03413895190494673\ \(0\)\
\-\ vertebral\\:\\ 0\\.03412525729200527\ \(0\)\
\-\ minimal\\:\\ 0\\.03409199212578653\ \(0\)\
\-\ system\\:\\ 0\\.03409199212578653\ \(0\)\
\-\ leg\\:\\ 0\\.03373510522415615\ \(0\)\
\-\ midline\\:\\ 0\\.03360925617437446\ \(0\)\
\-\ used\\:\\ 0\\.03345473568407018\ \(0\)\
\-\ cord\\:\\ 0\\.03312515253417115\ \(0\)\
\-\ view\\:\\ 0\\.03272479137287949\ \(0\)\
\-\ mid\\:\\ 0\\.03216018129215319\ \(0\)\
\-\ cortical\\:\\ 0\\.03208274473208633\ \(0\)\
\-\ spinal\\:\\ 0\\.031731163013650796\ \(0\)\
\-\ wbc\\:\\ 0\\.03158518484807057\ \(0\)\
\-\ quadrant\\:\\ 0\\.03130114401140563\ \(0\)\
\-\ because\\:\\ 0\\.031231714296624462\ \(0\)\
\-\ weight\\:\\ 0\\.03116289451401104\ \(0\)\
\-\ less\\:\\ 0\\.030401720036570924\ \(0\)\
\-\ palpation\\:\\ 0\\.030136828342279282\ \(0\)\
\-\ cases\\:\\ 0\\.030057092947841257\ \(0\)\
\-\ three\\:\\ 0\\.02999781951344196\ \(0\)\
\-\ body\\:\\ 0\\.029410235904774082\ \(0\)\
\-\ several\\:\\ 0\\.029319459282175716\ \(0\)\
\-\ no\\:\\ 0\\.029063807766054526\ \(0\)\
\-\ frontal\\:\\ 0\\.028762144537756804\ \(0\)\
\-\ will\\:\\ 0\\.028762144537756804\ \(0\)\
\-\ such\\:\\ 0\\.028745351530525914\ \(0\)\
\-\ usually\\:\\ 0\\.028132509294961805\ \(0\)\
\-\ decreased\\:\\ 0\\.02768042609306888\ \(0\)\
\-\ demonstrated\\:\\ 0\\.027463805797476218\ \(0\)\
\-\ pulmonary\\:\\ 0\\.027239161448016715\ \(0\)\
\-\ loss\\:\\ 0\\.0272253327862204\ \(0\)\
\-\ month\\:\\ 0\\.027183992664569244\ \(0\)\
\-\ appearance\\:\\ 0\\.026940431030287225\ \(0\)\
\-\ include\\:\\ 0\\.02658872401800889\ \(0\)\
\-\ secondary\\:\\ 0\\.026487476277536927\ \(0\)\
\-\ presented\\:\\ 0\\.026059285833432536\ \(0\)\
\-\ enhancement\\:\\ 0\\.025721413229034346\ \(0\)\
\-\ therapy\\:\\ 0\\.025675933073002907\ \(0\)\
\-\ one\\:\\ 0\\.025585757287406283\ \(0\)\
\-\ mild\\:\\ 0\\.02533213837241433\ \(0\)\
\-\ than\\:\\ 0\\.02533213837241433\ \(0\)\
\-\ over\\:\\ 0\\.024848278563540643\ \(0\)\
\-\ metastatic\\:\\ 0\\.024508921320204782\ \(0\)\
\-\ abdominal\\:\\ 0\\.02444084200396523\ \(0\)\
\-\ bone\\:\\ 0\\.02438295552230585\ \(0\)\
\-\ physical\\:\\ 0\\.024230650654708044\ \(0\)\
\-\ upper\\:\\ 0\\.02388036933630427\ \(0\)\
\-\ noted\\:\\ 0\\.023693307995751638\ \(0\)\
\-\ man\\:\\ 0\\.02365817818408734\ \(0\)\
\-\ associated\\:\\ 0\\.023553724171623647\ \(0\)\
\-\ imaging\\:\\ 0\\.02348485397093787\ \(0\)\
\-\ can\\:\\ 0\\.023450644593984896\ \(0\)\
\-\ demonstrate\\:\\ 0\\.023231852385428495\ \(0\)\
\-\ posterior\\:\\ 0\\.02310835111709059\ \(0\)\
\-\ exam\\:\\ 0\\.02249576770110658\ \(0\)\
\-\ had\\:\\ 0\\.022265012793813113\ \(0\)\
\-\ lateral\\:\\ 0\\.022177481884606616\ \(0\)\
\-\ but\\:\\ 0\\.022098095407368148\ \(0\)\
\-\ findings\\:\\ 0\\.022055130391773512\ \(0\)\
\-\ treatment\\:\\ 0\\.021287082185939235\ \(0\)\
\-\ which\\:\\ 0\\.020319903123893444\ \(0\)\
\-\ that\\:\\ 0\\.019392749019105694\ \(0\)\
\-\ as\\:\\ 0\\.01795260089280209\ \(0\)\
\-\ ct\\:\\ 0\\.017012994562361678\ \(0\)\
\-\ are\\:\\ 0\\.0169569174805836\ \(0\)\
\-\ at\\:\\ 0\\.016879077884727454\ \(0\)\
\-\ year\\:\\ 0\\.01377184309364169\ \(0\)\
\-\ old\\:\\ 0\\.013225736611689501\ \(0\)\
